| No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
| 1 |
rs554304889 |
chr12:124032883-124032884 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 2 |
rs116519775 |
chr12:124032932-124032933 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 3 |
rs540493638 |
chr12:124032964-124032965 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 4 |
rs576758516 |
chr12:124033027-124033028 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 5 |
rs367653558 |
chr12:124033053-124033054 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 6 |
rs148907879 |
chr12:124033062-124033063 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 7 |
rs191202521 |
chr12:124033076-124033077 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 8 |
rs562572993 |
chr12:124033086-124033087 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 9 |
rs142716557 |
chr12:124033108-124033109 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 10 |
rs548815572 |
chr12:124033153-124033154 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 11 |
rs373637970 |
chr12:124033173-124033174 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 12 |
rs182243280 |
chr12:124033237-124033238 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 13 |
rs151031733 |
chr12:124033302-124033303 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 14 |
rs186912242 |
chr12:124033364-124033365 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 15 |
rs28498381 |
chr12:124033365-124033366 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
| 16 |
rs549720281 |
chr12:124033367-124033368 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 17 |
rs568227298 |
chr12:124033397-124033398 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 18 |
rs535856334 |
chr12:124033409-124033410 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 19 |
rs112978027 |
chr12:124033422-124033423 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 20 |
rs376572979 |
chr12:124033430-124033431 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 21 |
rs554365742 |
chr12:124033442-124033443 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 22 |
rs145052419 |
chr12:124033450-124033451 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 23 |
rs552411073 |
chr12:124033472-124033473 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 24 |
rs533877073 |
chr12:124033478-124033479 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 25 |
rs368739182 |
chr12:124033496-124033497 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 26 |
rs372334474 |
chr12:124033500-124033501 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 27 |
rs577016012 |
chr12:124033514-124033515 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 28 |
rs537249452 |
chr12:124033530-124033531 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 29 |
rs146816492 |
chr12:124033534-124033535 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 30 |
rs376317536 |
chr12:124033542-124033543 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 31 |
rs191522161 |
chr12:124033543-124033544 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 32 |
rs61100007 |
chr12:124033603-124033604 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 33 |
rs140642492 |
chr12:124033630-124033631 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 34 |
rs542372764 |
chr12:124033640-124033641 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 35 |
rs527875264 |
chr12:124033677-124033678 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 36 |
rs369557883 |
chr12:124033684-124033685 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 37 |
rs562037604 |
chr12:124033686-124033687 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 38 |
rs145812655 |
chr12:124033697-124033698 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 39 |
rs111554166 |
chr12:124033716-124033717 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
| 40 |
rs138312604 |
chr12:124033731-124033732 |
Weak transcription Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 41 |
rs535581776 |
chr12:124033798-124033799 |
Weak transcription Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 42 |
rs547855609 |
chr12:124033799-124033800 |
Weak transcription Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 43 |
rs566592039 |
chr12:124033814-124033815 |
Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 44 |
rs533992633 |
chr12:124033836-124033837 |
Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 45 |
rs78406245 |
chr12:124033837-124033838 |
Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 46 |
rs149634936 |
chr12:124033838-124033839 |
Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 47 |
rs143412133 |
chr12:124033858-124033859 |
Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 48 |
rs184709793 |
chr12:124033867-124033868 |
Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 49 |
rs556220699 |
chr12:124033868-124033869 |
Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
Overlapped CNVs
|
n/a
|
| 50 |
rs7315326 |
chr12:124033885-124033886 |
Enhancers
|
Chromatin interactive region
|
1 gene(s)
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|